Document:

exv10w2

 

Exhibit 10.2

THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR THE LAWS OF ANY
STATE. THEY MAY NOT BE SOLD OR OTHERWISE TRANSFERRED UNLESS THEY ARE REGISTERED UNDER SUCH ACT AND
APPLICABLE STATE SECURITIES LAWS OR AN EXEMPTION FROM REGISTRATION IS AVAILABLE. THE SHARES
ISSUABLE UPON EXERCISE OF THESE SECURITIES MAY NOT BE SOLD, TRANSFERRED, OR OTHERWISE DISPOSED OF
BY THE HOLDER EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT FILED UNDER THE SECURITIES ACT
OF 1933, AS AMENDED, AND IN COMPLIANCE WITH APPLICABLE SECURITIES LAWS OF ANY STATE WITH RESPECT
THERETO OR IN ACCORDANCE WITH AN OPINION OF COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE
ISSUER THAT AN EXEMPTION FROM SUCH REGISTRATION IS AVAILABLE AND ALSO MAY NOT BE SOLD, TRANSFERRED
OR OTHERWISE DISPOSED OF EXCEPT IN COMPLIANCE WITH ANY APPLICABLE RULES OF THE SECURITIES AND
EXCHANGE COMMISSION.

                     Warrants

REGEN BIOLOGICS, INC.

WARRANT CERTIFICATE

Warrant to Purchase

Preferred or Common Stock

Date of Issue: March 2, 2007

     This warrant certificate (“Warrant Certificate”) certifies that for value received
                     or registered assigns (the “Holder”) is the owner of the warrant specified above
(the “Warrant”), which entitles the Holder thereof to purchase, at any time on or before the
Expiration Date (hereinafter defined) (i) up to                      fully paid and non-assessable
shares of Series D Convertible Preferred Stock, $0.01 par value (“Preferred Stock”), of ReGen
Biologics, Inc., a Delaware corporation (the “Company”), or (ii) after the Mandatory Conversion (as
hereinafter defined) of the Preferred Stock, up to                      fully paid and non-assessable
shares of Common Stock, $0.01 par value (“Common Stock”), of ReGen Biologics, Inc., a Delaware
corporation (the “Company”), at the Exercise Price (as defined herein). “Mandatory Conversion”
means the conversion of the Preferred Stock pursuant to Paragraph 7(a) of the Certificate of
Designations, Preferences and Rights in the form attached hereto as Exhibit A.

     1. Warrant; Exercise Price

     This Warrant shall entitle the Holder to purchase up to (i)                    shares of Preferred Stock
of the Company and the purchase price payable upon exercise of the Warrants shall

 

 

initially be $63.00 per share of Preferred Stock, subject to adjustment as hereinafter
provided (as may be adjusted from time to time, the “Preferred Exercise Price”) or, (ii) after the
Mandatory Conversion of the Preferred Stock,                     shares of Common Stock of the Company and
the purchase price payable upon exercise of the Warrants shall initially be $0.63 per share of
Common Stock, subject to adjustment as hereinafter provided (as may be adjusted from time to time,
the “Common Exercise Price” and together with the Preferred Exercise Price, the “Exercise Price”).
The Exercise Price and number of shares of Preferred Stock or, after the Mandatory Conversion,
Common Stock, issuable upon exercise of this Warrant are subject to adjustment as provided in
Article 6.

     2. Exercise; Expiration Date

     2.1 This Warrant is exercisable, at the option of the Holder, at any time or times
after issuance and on or before the Expiration Date (as hereinafter defined), upon surrender
of this Warrant Certificate to the Company together with a duly completed Notice of
Exercise, in the form attached hereto as Exhibit B, and payment of an amount equal
to the product of (i) the Preferred Exercise Price times the number of shares of Preferred
Stock to be acquired, or (ii) after the Mandatory Conversion, the Common Exercise Price
times the number of shares of Common Stock to be acquired. Payment of the Exercise Price
for the Warrant Shares (as hereinafter defined) shall be in lawful money of the United
States of America, paid by wired transfer or cashier’s check drawn on a United States bank
or pursuant to the terms of Section 9. In the case of exercise of the Warrant for less than
all the Warrant Shares (as hereinafter defined) represented by this Warrant Certificate, the
Company shall cancel the Warrant Certificate upon the surrender thereof and shall execute
and deliver a new Warrant Certificate for the balance of such Warrant Shares (as hereinafter
defined).

     2.2 The term “Expiration Date” shall mean 5:00 p.m. New York time on March 2, 2012 or
if such date shall in the State of New York be a holiday or a day on which banks are
authorized to close, then 5:00 p.m. New York time the next following date which in the State
of New York is not a holiday or a day on which banks are authorized to close.

     3. Registration and Transfer on Company Books

     3.1 The Company shall maintain books for the registration and transfer of the Warrants
and the registration and transfer of the shares of Preferred Stock or, after the Mandatory
Conversion, Common Stock, issued upon exercise of the Warrants.

     3.2 Prior to due presentment for registration of transfer of this Warrant Certificate,
or the shares of Preferred Stock or, after the Mandatory Conversion, Common Stock, issued
upon exercise of the Warrants, the Company may deem and treat the registered Holder as the
absolute owner thereof.

     3.3 Neither this Warrant nor the shares of Preferred Stock or, after the Mandatory
Conversion, Common Stock, issuable upon exercise hereof (the “Warrant Shares”) have been
registered under the Securities Act of 1933, as amended (the “Act”).

2

 

The Company will not transfer this Warrant or issue or transfer the Warrant Shares
unless (i) there is an effective registration covering such Warrant or Warrant Shares, as
the case may be, under the Act and applicable states securities laws, (ii) it first receives
a letter from an attorney, acceptable to the Company’s board of directors or its agents,
stating that in the opinion of the attorney the proposed issue or transfer is exempt from
registration under the Act and under all applicable state securities laws, or (iii) the
transfer is made pursuant to Rule 144 under the Act. Subject to the foregoing, this Warrant
Certificate, the Warrant represented hereby, and the Warrant Shares, may be sold, assigned
or otherwise transferred voluntarily by the Holder to officers or directors of the Holder,
to members of such persons’ immediate families, or to the Holder’s parent or subsidiary
corporations. The Company shall register upon its books any permitted transfer of a Warrant
Certificate, upon surrender of same to the Company with a written instrument of transfer
duly executed by the registered Holder or by a duly authorized attorney. Upon any such
registration of transfer, new Warrant Certificate(s) shall be issued to the transferee(s)
and the surrendered Warrant Certificate shall be canceled by the Company. A Warrant
Certificate may also be exchanged, at the option of the Holder, for new Warrant Certificates
representing in the aggregate the number of Warrant Shares evidenced by the Warrant
Certificate surrendered.

     4. Reservation of Shares

     The Company covenants that it will at all times reserve and keep available out of its
authorized Preferred Stock, or, after the Mandatory Conversion, Common Stock, solely for the
purpose of issue upon exercise of the Warrant, such number of shares of Preferred Stock or Common
Stock as shall then be issuable upon the exercise of the entire Warrant. The Company covenants
that all Warrant Shares shall be duly and validly issued and, upon payment for such shares as set
forth herein, fully paid and non-assessable and free from all taxes, liens and charges with respect
to the issue thereof, and, with regard to the Common Stock, that upon issuance such shares shall be
listed on each national securities exchange, if any, on which the other shares of outstanding
Common Stock of the Company are then listed.

     5. Loss or Mutilation

     Upon receipt by the Company of reasonable evidence of the ownership of and the loss, theft,
destruction or mutilation of any Warrant Certificate and, in the case of loss, theft or
destruction, of indemnity reasonably satisfactory to the Company, or, in the case of mutilation,
upon surrender and cancellation of the mutilated Warrant Certificate, the Company shall execute and
deliver in lieu thereof a new Warrant Certificate representing the number of Warrant Shares
evidenced by the lost, stolen, destroyed or mutilated Warrant Certificate.

     6. Adjustments of Exercise Price and Shares

     6.1 In the event of changes in the outstanding Preferred Stock or Common Stock of the
Company by reason of stock dividends, split-ups, recapitalizations, reclassifications,
combinations or exchanges of shares, separations, reorganizations, liquidations,
consolidation, acquisition of the Company (whether through merger or acquisition of
substantially all the assets or stock of the Company), or the like, the

3

 

number and class of shares available under the Warrant in the aggregate and the
Exercise Price shall be correspondingly adjusted to give the Holder of the Warrant, on
exercise for the same aggregate Exercise Price, the total number, class, and kind of shares
or other property as the Holder would have owned had the Warrant been exercised prior to the
event and had the Holder continued to hold such shares until the event requiring adjustment.
The form of this Warrant need not be changed because of any adjustment in the number of
Warrant Shares subject to this Warrant or the Exercise Price provided herein.

     6.2 If at any time or from time to time the holders of all of the shares of Preferred
Stock or, after the Mandatory Conversion, Common Stock, of the Company (or the holders of
all of the shares of stock or other securities at the time receivable upon the exercise of
this Warrant) shall, as a class, have received or become entitled to receive, without
payment therefor:

	 	(i)	 	Common Stock or any shares of stock or other
securities which are at any time directly or indirectly convertible
into or exchangeable for Common Stock, or any rights or options to
subscribe for, purchase or otherwise acquire any of the foregoing by
way of dividend or other distribution (other than a dividend or
distribution covered in Section 6.1 above),
	 
	 	(ii)	 	any cash paid or payable otherwise than as a
cash dividend; or
	 
	 	(iii)	 	Common Stock or additional stock or other
securities or property (including cash) by way of spinoff, split-up,
reclassification, combination of shares or similar corporate
rearrangement (other than shares of Common Stock pursuant to Section
6.1 above),

then, and in each such case, the Holder hereof will, upon the exercise of this Warrant, be
entitled to receive, in addition to the number of shares of Preferred Stock or, after the
Mandatory Conversion, Common Stock receivable thereupon, and without payment of any
additional consideration therefor, the amount of stock and other securities and property
(including cash in the cases referred to in clauses (ii) and (iii) above) which such Holder
would hold on the date of such exercise had he been the holder of record of such Preferred
Stock or, after the Mandatory Conversion, Common Stock, as of the date on which holders of
Preferred Stock or, after the Mandatory Conversion, Common Stock, received or became
entitled to receive such shares or all other additional stock and other securities and
property.

     6.3 Whenever the number of Warrant Shares purchasable upon the exercise of the Warrant
or the Exercise Price of such Warrant Shares is adjusted, as herein provided, the Company
shall mail to the Holder, at the address of the Holder shown on the books of the Company, a
notice of such adjustment or adjustments, prepared and signed by the Chief Financial Officer
or Secretary of the Company, which sets forth the number of Warrant Shares purchasable upon
the exercise of each Warrant and the Exercise Price of

4

 

such Warrant Shares after such adjustment, a brief statement of the facts requiring
such adjustment and the computation by which such adjustment was made.

     7. Conversion 

     7.1 In lieu of exercise of any portion of the Warrant as provided in Section 2.1
hereof, the Warrants represented by this Warrant Certificate (or any portion thereof) may,
at the election of the Holder, be converted into the nearest whole number of shares of
Preferred Stock or, after the Mandatory Conversion, Common Stock, equal to: (1) the product
of (a) the number of Warrants to be so converted, (b) the number of shares of Preferred
Stock or, after the Mandatory Conversion, Common Stock, then issuable upon the exercise of
each Warrant and (c) the excess, if any, of (i) the Preferred Stock Market Price Per Share
(as determined pursuant to Section 8.3) or, after the Mandatory Conversion, Common Stock
Market Price Per Share (as determined pursuant to Section 8.2) with respect to the date of
conversion over (ii) the Exercise Price in effect on the business day next preceding the
date of conversion, divided by (2) the Preferred Stock Market Price Per Share or, after the
Mandatory Conversion, Common Stock Market Price Per Share with respect to the date of
conversion.

     7.2 The conversion rights provided under this Section 7 may be exercised in whole or in
part and at any time and from time to time while any Warrants remain outstanding. In order
to exercise the conversion privilege, the Holder shall surrender to the Company, at its
offices, this Warrant Certificate accompanied by a duly completed Notice of Conversion in
the form attached hereto as Exhibit C. The Warrants (or so many thereof as shall
have been surrendered for conversion) shall be deemed to have been converted immediately
prior to the close of business on the day of surrender of such Warrant Certificate for
conversion in accordance with the foregoing provisions. As promptly as practicable on or
after the conversion date, the Company shall issue and shall deliver to the Holder (i) a
certificate or certificates representing the number of shares of Common Stock to which the
Holder shall be entitled as a result of the conversion, and (ii) if the Warrant Certificate
is being converted in part only, a new certificate in principal amount equal to the
unconverted portion of the Warrant Certificate.

     8. Fractional Shares and Warrants; Determination of Market Price Per Share

     8.1 Anything contained herein to the contrary notwithstanding, the Company shall not be
required to issue any fraction of a share of Preferred Stock or, after the Mandatory
Conversion, Common Stock, in connection with the exercise of Warrants. Warrants may not be
exercised in such number as would result (except for the provisions of this paragraph) in
the issuance of a fraction of a share of Preferred Stock or, after the Mandatory Conversion,
Common Stock, unless the Holder is exercising the entire Warrant then owned by the Holder.
In such event, the Company shall, upon the exercise of the Warrant, issue to the Holder the
largest aggregate whole number of shares of Preferred Stock or, after the Mandatory
Conversion, Common Stock, called for thereby upon receipt of the Exercise Price for the
entire Warrant and pay a sum in cash equal to the remaining fraction of a share of Preferred
Stock or, after the Mandatory Conversion, Common Stock, multiplied by the Preferred Stock
Market Price Per Share (as determined

5

 

pursuant to Section 8.3 below) or, after the Mandatory Conversion, the Common Stock
Market Price Per Share (as determined pursuant to Section 8.2 below) as of the last business
day preceding the date on which the Warrants are presented for exercise.

     8.2 As used herein, the “Common Stock Market Price Per Share” with respect to any date
shall mean the average closing price per share of Company’s Common Stock for the ten (10)
trading days immediately preceding such date during which the Common Stock has traded. The
closing price for each such day shall be the closing sale price or, in case no such sale
takes place on such day, the closing price on the last trading day, in either case on the
principal securities exchange on which the shares of Common Stock of the Company are listed
or admitted to trading, the last sale price, or in case no sale takes place on any such day,
the average of the high and low sales prices of the Common Stock on the Over-the-Counter
Bulletin Board (“OTCBB”) or any comparable system, or if the Common Stock is not reported on
OTCBB, or a comparable system, the average of the closing bid and asked prices as furnished
by two members of the National Association of Securities Dealers, Inc. selected from time to
time by the Company for that purpose. If such bid and asked prices are not available, then
“Common Stock Market Price Per Share” shall be equal to the fair market value of the
Company’s Common Stock as determined in good faith by the Board of Directors of the Company.

     8.3 “Preferred Stock Market Price Per Share” with respect to any date shall mean the
Common Stock Market Price Per Share (as determined pursuant to Section 8.2) multiplied by
100.

     9. Notices.

     All notices, requests, demands, claims, and other communications hereunder shall be in writing
and shall be delivered by certified or registered mail (first class postage pre-paid), guaranteed
overnight delivery, or facsimile transmission if such transmission is confirmed by delivery by
certified or registered mail (first class postage pre-paid) or guaranteed overnight delivery, to
the following addresses and telecopy numbers (or to such other addresses or telecopy numbers which
such party shall subsequently designate in writing to the other party):

if to the Company to:

ReGen Biologics, Inc.

509 Commerce Street

Franklin Lakes, NJ 07417

Attention: Brion D. Umidi

Telecopy: 201.651.5141

with a copy to:

Pillsbury Winthrop Shaw Pittman LLP

1650 Tysons Boulevard

McLean, VA 22102

6

 

Attention: David C. Main, Esq.

Telecopy: 703.770.7901

if to the Holder to the address set forth on the books of the Company.

     Each such notice or other communication shall for all purposes of this Agreement be treated as
effective or having been given when delivered if delivered by hand, by messenger or by courier, or
if sent by facsimile, upon confirmation of receipt.

     10. Governing Law

This Warrant Certificate shall be governed by and construed in accordance with the laws of the
State of New York.

7

 

     IN WITNESS WHEREOF, the Company has caused this Warrant Certificate to be duly executed by its
officers thereunto duly authorized and its corporate seal to be affixed hereon, as of this
2nd day of March, 2007.

REGEN BIOLOGICS, INC.

	 	 	 	 	 
	By:

	 	 	 	 
	 

	 	 	 	 
	 

	 	Name: Brion D. Umidi	 	 
	 

	 	Title: Senior Vice President and Chief	 	 
	 

	 	Financial Officer	 	 
	 
	 	 	 	 
	Attest:	 	 
	 
	 	 	 	 
	 	 	 
	Name:
	 	 	 	 
	Title:
	 	 	 	 

8

 

EXHIBIT A

Certificate of Designations, Preferences and Rights

of Series D Convertible Preferred Stock

9

 

EXHIBIT B

NOTICE OF EXERCISE

	 	 	 	 	 
	To:

	 	ReGen Biologics, Inc.	 	 
	 

	 	509 Commerce Street
	 	                    , 20          
	 

	 	Franklin Lakes, NJ 07417	 	 

     The undersigned hereby irrevocably elects to purchase, pursuant to Section 2 of the Warrant
Certificate accompanying this Notice of Exercise,                      Warrant Shares of the total number of
Warrant Shares issuable to the undersigned pursuant to the accompanying Warrant Certificate, and
herewith makes payment of $                     in payment in full of the aggregate Exercise Price of such
shares.

     Please issue a certificate or certificates representing said Warrant Shares in the name of the
undersigned or in such other name as is specified below:

	 	 	 	 	 
	 
	 	 	 	 
	 

	 	 

	 	 
	 
	 	 	 	 
	 	 	The Warrant Shares shall be delivered to the following:
	 
	 	 	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	 

	 	 	 	 

	 	 	 	 	 
	 
	 	 	 	 
	 

	 	 

	 	 
	 

	 	Name of Holder	 	 
	 
	 	 	 	 
	 

	 	 	 	 
	 

	 	Signature	 	 
	 
	 	 	 	 
	 

	 	Address:	 	 
	 
	 	 	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	 

	 	 	 	 

10

 

EXHIBIT C

NOTICE OF CONVERSION

	 	 	 	 	 
	To:

	 	ReGen Biologics, Inc.	 	 
	 

	 	509 Commerce Street
	 	                    , 20          
	 

	 	Franklin Lakes, NJ 07417	 	 

     The undersigned hereby irrevocably elects to convert, pursuant to Section 7 of the Warrant
Certificate accompanying this Notice of Conversion,                      Warrant Shares of the total number of
Warrant Shares issuable to the undersigned pursuant to the accompanying Warrant Certificate into
shares of the Preferred Stock /Common Stock (circle one) of the Company (the “Shares”).

     The number of Shares to be received by the undersigned, calculated in accordance with the
provisions of Section 7.1 of the accompanying Warrant Certificate, is                     .

	 	 	 	 	 
	 
	 	 	 	 
	 

	 	 

	 	 

     Please issue a certificate or certificates representing said Warrant Shares in the name of the
undersigned or in such other name as is specified below:

	 	 	 	 	 
	 
	 	 	 	 
	 

	 	 

	 	 
	 
	 	 	 	 
	The Warrant Shares shall be delivered to the following:
	 
	 	 	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	 

	 	 	 	 

	 	 	 	 	 
	 
	 	 	 	 
	 

	 	 

	 	 
	 

	 	Name of Holder	 	 
	 
	 	 	 	 
	 

	 	 	 	 
	 

	 	Signature	 	 
	 
	 	 	 	 
	 

	 	Address:	 	 
	 
	 	 	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	 

	 	 	 	 

11exv10w3

 

Exhibit 10.3

OPTION AGREEMENT

     This Option Agreement (“Option Agreement”) is made as of the 2nd day of March, 2007
(the “Effective Date”), by and between ReGen Biologics, Inc., a Delaware corporation (hereinafter
referred to as the “Company”), and the undersigned investor (together with its successors and
permitted assigns, the “Holder”).

RECITALS

     WHEREAS, in order to induce the Holder to enter into that certain Subscription Agreement
between the Company and the Holder dated as of March 2, 2007 (the “Subscription Agreement”), the
parties have entered into this Option Agreement granting to the Holder an option to purchase,
pursuant to the terms and conditions set forth herein, the Option Shares (as hereinafter defined);

     NOW, THEREFORE, BE IT RESOLVED, in consideration of the mutual covenants expressed herein and
for other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, and intending to be legally bound, the parties agree as follows:

AGREEMENT

	 	1.	 	GRANT AND VESTING OF OPTION.

	 	(a)	 	Grant. Subject to the terms hereof, the Company hereby
grants to the Holder the option (the “Option”) to purchase from the Company
such number of shares (the “Option Shares”) of : (i) the Company’s Series D
Convertible Preferred Stock, $0.01 par value per share (the “Preferred Stock”),
equal to the number of shares purchased by the Holder pursuant to the
Subscription Agreement; or (ii) if the Preferred Stock has been
converted to shares of the Company’s Common Stock, $0.01 par value per share (the “Common
Stock”) pursuant to paragraph 7(a) of the Company’s Certificate of
Designations, Preferences and Rights of Series D Convertible Preferred Stock
(the “Mandatory Conversion”), such number of shares of Common Stock equal to
the number of shares of Common Stock such Holder would have been entitled to
receive upon conversion of the Preferred Stock such Holder purchased pursuant
to the Subscription Agreement.
	 
	 	(b)	 	Vesting. The Holder may exercise this Option upon, and
not later than fifteen (15) calendar days following, the Company’s public
announcement of receipt of Food and Drug Administration clearance of the
Company’s collagen scaffold device as a class II device (the last date of such
15-day period, the “Expiration Date”). In no event shall this Option be
exercised later than the Termination Date provided for below.

 

 

	 	(c)	 	Exercise Price. The “Exercise Price” (which shall be
subject to adjustment whenever there shall occur a stock split, combination,
reclassification or other similar event involving the Preferred Stock or the
Common Stock, as applicable) shall be (i) $42.00 per share of Preferred Stock
or (ii) if applicable pursuant to Paragraph 1(a)(ii) of this Option Agreement,
$0.42 per share of Common Stock.
	 
	 	(d)	 	Term. The Option shall terminate upon the earlier of
(i) the Expiration Date, (ii) December 31, 2007 (the “Termination Date”) and
(iii) partial exercise as provided by Section 2 below.

	 	2.	 	EXERCISE OF OPTION. In order to exercise the Option, the Holder must
present at the Company’s principal executive offices the following:

	 	(a)	 	the original Option Agreement together with a fully executed
Option Exercise Form in the form attached hereto and made a part hereof as
Exhibit A, including the representation to the Company that all of the
representations and warranties made by the Holder in Section 6(b) of this
Option Agreement are true and correct on the date of exercise; and
	 
	 	(b)	 	a certified or bank cashier’s check payable to the Company or a
wire transfer of immediately available funds in the amount of the product of
the Option Shares to be exercised and the Exercise Price (such amount, the
“Exercise Amount”).

The Company shall promptly thereafter deliver, or cause to be delivered, to the
Holder certificates for the number of Option Shares being purchased. If the Holder
elects to exercise the Option for less than all of the Options Shares subject
hereto, the option to purchase the remainder of the Option Shares shall immediately
terminate.

	 	3.	 	TRANSFER. This Option may not be transferred or assigned in any
manner, without the consent of the Company in its sole and absolute discretion.
	 
	 	4.	 	RIGHTS AND OBLIGATIONS OF THE HOLDER. The Holder shall not, by virtue
hereof, be entitled to any rights as a stockholder in the Company, either at law or in
equity; provided, however, in the event that any certificate representing Option Shares
is issued to the Holder upon exercise of some or all of the Option, the Holder shall,
for all purposes, be deemed to have become the holder of record of such Option Shares
on the date on which full payment of the Exercise Amount was made, irrespective of the
date of delivery of the certificate representing such Option Shares. The rights of the
Holder are limited to those expressed herein.
	 
	 	5.	 	REGISTRATION RIGHTS. The Holder shall have the following registration
rights with respect to the Option Shares:

	 	(a)	 	Required Registration. Following the Mandatory
Conversion, the Company agrees to register the resale of the Option Shares by
filing a Registration Statement on Form S-1 or on any other form for which the

 - 2 - 

 

	 	 	 	Company then qualifies and is available (the “Registration Statement”) with
the SEC within the earlier of (i) thirty (30) calendar days after the filing
of the Company’s Form 10-K for the prior fiscal year or (ii) ninety (90)
calendar days after the Expiration Date, or registering such Option Shares
on any Registration Statement filed by the Company. The Company shall
subsequently use commercially reasonable efforts to cause the SEC to declare
the Registration Statement effective as soon as possible. The Company shall
thereafter maintain the effectiveness of the Registration Statement until
the earlier of (a) the date on which all the Option Shares have been sold
pursuant to the Registration Statement or Rule 144 promulgated under the
Securities Act (“Rule 144”), (b) such time as the Company reasonably
determines, based on an opinion of counsel, that all of the holders of
options granted contemporaneously with the Option will be eligible to sell
under Rule 144 all of the Option Shares then owned by such holders within
the volume limitations imposed by paragraph (e) of Rule 144 in the three (3)
month period immediately following the termination of the effectiveness of
the Registration Statement, and (c) the first anniversary of the date the
Registration Statement was declared effective by the SEC. The Registration
Statement filed pursuant to this Section 5(a) may include other securities
of the Company that are held by individuals, partnerships, corporations,
business trusts, joint stock companies, estates, trusts, unincorporated
associations, joint ventures or other entities who, by virtue of agreements
with the Company, are entitled to similar registration rights.
	 
	 	(b)	 	Registration Procedures.

	 	i.	 	In case of the Registration Statement effected
by the Company subject to this Section 5, the Company shall keep the
Holder advised in writing as to the initiation of such registration,
and as to the completion thereof. In addition, subject to Section 5(a)
above, the Company shall, to the extent applicable to the Registration
Statement:

	 	a)	 	prepare and file with the SEC
such amendments and supplements to the Registration Statement as
may be necessary to keep such registration continuously
effective and free from any material misstatement or omission
necessary to make the statements therein, in light of the
circumstances, not misleading, and comply with provisions of the
Securities Act with respect to the disposition of all securities
covered thereby during the period referred to in Section 5(a);
	 
	 	b)	 	update, correct, amend and
supplement the Registration Statement as necessary;
	 
	 	c)	 	notify the Holder promptly when
the Registration Statement is declared effective by the SEC, and
furnish

 - 3 - 

 

	 	 	 	such number of prospectuses, including preliminary
prospectuses, and other documents incident thereto as Holder
may reasonably request from time to time;
	 
	 	d)	 	use its commercially reasonable
efforts to register or qualify such Option Shares under such
other securities or blue sky laws of such jurisdictions of the
United States where an exemption is not available and as Holder
may reasonably request to enable it to consummate the
disposition in such jurisdiction of the Option Shares (provided
that the Company will not be required to (A) qualify generally
to do business in any jurisdiction where it would not otherwise
be required to qualify but for this provision, or (B) consent to
general service of process in any such jurisdiction, or (C)
subject itself to taxation in any jurisdiction where it is not
already subject to taxation);
	 
	 	e)	 	notify Holder at any time when a
prospectus relating to the Option Shares is required to be
delivered under the Securities Act, of the happening of any
event as a result of which the prospectus included in the
Registration Statement contains an untrue statement of a
material fact or omits any fact necessary to make the statements
therein not misleading and, subject to Section 5(a), the Company
will prepare a supplement or amendment to such prospectus, so
that, as thereafter delivered to purchasers of such shares, such
prospectus will not contain any untrue statements of a material
fact or omit to state any fact necessary to make the statements
therein, in light of the circumstances under which they were
made, not misleading;
	 
	 	f)	 	cause all such Option Shares to
be listed on each securities exchange on which similar
securities issued by the Company are then listed and obtain all
necessary approvals for trading thereon;
	 
	 	g)	 	provide a transfer agent and
registrar for all such Option Shares not later than the
effective date of the Registration Statement;
	 
	 	h)	 	upon the sale of any Option
Shares pursuant to the Registration Statement, direct the
transfer agent to remove all restrictive legends from all
certificates or other instruments evidencing the Option Shares;
	 
	 	i)	 	With a view to making available
to the Holder the benefits of certain rules and regulations of
the SEC that at any time permit the sale of the Option Shares to
the public without registration, so long as any Option Shares
are outstanding,

 - 4 - 

 

	 	 	 	the Company shall use its commercially reasonable efforts for
a period of two years following the Effective Date:

	 	(1)	 	to make and keep
public information available, as those terms are
understood and defined in Rule 144(c) under the
Securities Act;
	 
	 	(2)	 	to file with the
SEC in a timely manner all reports and other documents
required of the Company under the Exchange Act; and
	 
	 	(3)	 	to furnish to the
Holder upon any reasonable request a written statement
by the Company as to its compliance with the public
information requirements of Rule 144(c) under the
Securities Act; and

	 	j)	 	To advise the Holder promptly
after it has received notice or obtained knowledge of the
existence of any stop order by the SEC delaying or suspending
the effectiveness of the Registration Statement or of the
initiation or threat of any proceeding for that purpose, and to
make every commercially reasonable effort to obtain the
withdrawal of any order suspending the effectiveness of the
Registration Statement at the earliest possible time.

	 	ii.	 	Notwithstanding anything stated or implied to
the contrary in Section 5(b)(i) above, the Company shall not be
required to consent to any underwritten offering of the Option Shares
or to any specific underwriter participating in any underwritten public
offering of the Option Shares.
	 
	 	iii.	 	Each Holder agrees that upon receipt of any
notice from the Company of the happening of any event of the kind
described in Section 5(b)(i)(e), and subject to Section 5(d), such
Holder will forthwith discontinue such Holder’s disposition of Option
Shares pursuant to the registration statement relating to such Option
Shares until such Holder’s receipt of the copies of the supplemented or
amended prospectus contemplated by Section 5(b)(i)(e) and, if so
directed by the Company, will deliver to the Company at the Company’s
expense all copies, other than permanent file copies, then in such
Holder’s possession, of the prospectus relating to such Option Shares
current at the time of receipt of such notice.
	 
	 	iv.	 	Except as required by law, all expenses
incurred by the Company in complying with this Section 5, including but
not limited to, all registration, qualification and filing fees,
printing expenses, fees and disbursements of counsel and accountants
for the Company, blue sky fees and expenses (including fees and
disbursements of

 - 5 - 

 

	 	 	 	counsel related to all blue sky matters) incurred in connection with
any registration, qualification or compliance pursuant to this
Section 5 shall be borne by the Company. All underwriting discounts
and selling commissions applicable to a sale incurred in connection
with any registration of Option Shares and the legal fees and other
expenses of a Holder shall be borne by such Holder.

	 	(c)	 	Further Information. If Option Shares owned by a
Holder are included in any registration, such Holder shall furnish the Company
such information regarding itself as the Company may reasonably request and as
shall be required in connection with any registration (or amendment or
supplement thereto), referred to in this Agreement, and Holder shall indemnify
the Company with respect thereto in accordance with Section 9 hereof. The
Holder hereby represents and warrants to the Company that it has accurately and
completely provided the requested information and answered questions (a)
through (i) on the signature pages of the Subscription Agreement, and the
Holder agrees and acknowledges that the Company may rely on such information as
being true and correct for purposes of preparing and filing the Registration
Statement at the time of filing thereof and at the time it is declared
effective, unless the Holder has notified the Company in writing to the
contrary prior to such time.
	 
	 	(d)	 	Right of Suspension.

	 	i.	 	Notwithstanding any other provision of this
Agreement or any related agreement to the contrary, the Company shall
have the right, at any time, to suspend the effectiveness of the
Registration Statement and offers and sales of the Option Shares
pursuant thereto whenever, in the good faith judgment of the Company,
(i) continuing such effectiveness or permitting such offers and sales
could reasonably be expected to have an adverse effect upon the
Company’s ability to raise additional funds pursuant to one or more
private placements of shares of the Company or any debt securities of
the Company, a proposed sale of all or substantially all of the assets
of the Company or a merger, acquisition, reorganization,
recapitalization or similar current transaction materially affecting
the capital, structure, or equity ownership of the Company, (ii) the
Registration Statement must be suspended in order to register
additional shares of Preferred Stock or Common Stock, (iii) there
exists a material development or a potential material development with
respect to or involving the Company that the Company would be obligated
to disclose in the prospectus used in connection with the Registration
Statement, which disclosure, in the good faith judgment of the Company,
after considering the advice of counsel, would be premature or
otherwise inadvisable at such time, or (iv) the Registration Statement
or related prospectus or any document incorporated or deemed to be
incorporated therein by reference contains an untrue

 - 6 - 

 

	 	 	 	statement of a material fact or omits to state a material fact
required to be stated therein or necessary to make the statements
therein, in light of the circumstances, not misleading, including
without limitation that period annually during which any Registration
Statement would require suspension pending the Issuer’s new fiscal
year financial statements (a “Suspension Event”). In the event that
the Company shall determine to so suspend the effectiveness of the
Registration Statement and offers and sales of the Option Shares
pursuant thereto, the Company shall, in addition to performing those
acts required to be performed under the Securities Act and/or the
Exchange Act or deemed advisable by the Company, deliver to each
Holder written notice thereof, signed by the Chief Financial Officer
or Chief Executive Officer of the Company. Upon receipt of such
notice, the Holders shall discontinue disposition of the Option
Shares pursuant to the Registration Statement and prospectus until
such Holders (x) are advised in writing by the Company that the use
of the Registration Statement and prospectus (and offers and sales
thereunder) may be resumed, (y) have received copies of a
supplemental or amended prospectus, if applicable, and (z) have
received copies of any additional or supplemental filings which are
incorporated or deemed to be incorporated by reference into such
prospectus. The Company will exercise commercially reasonable
efforts to ensure that the use of the Registration Statement and
prospectus may be resumed as quickly as practicable.
	 
	 	ii.	 	The Company’s right to suspend the effectiveness of the Registration Statement and the offers and sales of
the Option Shares pursuant thereto, as described above in this Section
5(d), shall be for a period of time (the “Suspension Period”) beginning
on the date of the occurrence of the Suspension Event and expiring on
the earlier to occur of (i) the date on which the Suspension Event
ceases, or (ii) ninety (90) days after the occurrence of the Suspension
Event; provided, however, that there shall not be more than two
Suspension Periods in any 12-month period. Notwithstanding the
foregoing, the Company shall be able to suspend the effectiveness of
the Registration Statement and offers and sales of the Option Shares
for any time period as may reasonably be required in order to update
the Registration Statement to replace financial information which is no
longer current, as required by applicable securities law.
	 
	 	iii.	 	In addition, in connection with any
underwritten public offering of securities of the Company, if requested
by the Company or its managing underwriter, each Holder will enter into
a lock-up agreement pursuant to which such Holder will not, during the
seven (7) days prior to, and for a period no longer than one hundred
eighty (180) days following, the date of the prospectus (or

 - 7 - 

 

	 	 	 	if the offering is pursuant to a shelf registration statement, the
date of the pricing prospectus supplement) relating to the offering,
offer, sell or otherwise dispose of any securities of the Company
without the prior consent of the Company and the managing
underwriter, provided that the executive officers and directors of
the Company enter into lock-up agreements for a period at least as
long and on the same terms.

	 	6.	 	COVENANTS.

	 	(a)	 	The Company covenants and agrees that all Option Shares
delivered upon exercise (in accordance with the terms and conditions set forth
herein) of the Option will, upon delivery, be duly and validly authorized and
issued, fully paid and non-assessable, and free from all liens and charges with
respect to the purchase thereof.
	 
	 	(b)	 	The Company covenants and agrees that this Option Agreement has
been duly and validly authorized, executed and delivered. In addition, the
Company agrees at all times to reserve and keep available an authorized number
of (i) shares of the Preferred Stock sufficient to permit the exercise in full
of the Option or (ii) after the Mandatory Conversion, shares of its Common
Stock sufficient to permit the exercise in full of the Option.

	 	7.	 	REPRESENTATIONS AND WARRANTIES.

	 	(a)	 	The Option Shares will not be registered under the Securities
Act of 1933, as amended, or the rules and regulations promulgated thereunder
(such Act and rules and regulations being hereinafter referred to as the “Act”)
or any state securities laws. The Holder agrees that the sale or any other
disposition of the Option Shares will be made in compliance with federal and
applicable state securities laws.
	 
	 	(b)	 	The Holder hereby represents and warrants to the Company as
follows:

	 	i.	 	it is an “accredited investor” within the
meaning of Rule 501 under the Act;
	 
	 	ii.	 	it is sophisticated and experienced in matters
of equity investing in general and in financial and business matters
related to the business of the Company in particular, capable of
evaluating the merits and risks of an investment in the Option and the
Option Shares;
	 
	 	iii.	 	it is acquiring the Option and will acquire the
Option Shares for investment for its own account and not with a view to
any distribution thereof in violation of Federal or applicable state
securities laws;

 - 8 - 

 

	 	iv.	 	this Option Agreement and the transactions
hereby have been duly approved by all requisite action of the Holder,
and the Holder has full power and authority to enter into and perform
its obligations under this Option Agreement, and to otherwise carry out
the transactions contemplated by this Option Agreement, without the
consent or approval of, notice to or registration with any person,
association, entity or governmental authority;
	 
	 	v.	 	this Option Agreement is a legal, valid and
binding obligation of the Holder enforceable in accordance with its
terms; and
	 
	 	vi.	 	the execution, delivery, performance and
consummation of this Option Agreement and the transactions provided for
herein do not and will not violate: (a) any contract, agreement or
other commitment to which the Holder is a party, or by which the Holder
is bound; or (b) any order, writ, injunction, decree, statute,
ordinance, rule or regulation applicable to the Holder.

	 	8.	 	FRACTIONAL SHARES. The Company shall not be required to issue any
fraction of a share of Preferred Stock or, after the Mandatory Conversion, any fraction
of a share of Common Stock, upon the exercise of the Option. If any fractional
interest in a share of Preferred Stock or Common Stock, as the case may be, shall be
deliverable upon the exercise of the Option (in whole or in part), the Company shall
make an adjustment therefor in cash equal to such fraction multiplied by the closing
price of the Preferred Stock or Common Stock, as the case may be, on the business day
directly preceding the day of exercise. If there is no closing price, then the
fraction shall be multiplied by the fair market value of a share of Preferred Stock or
Common Stock, as the case may be, as determined by the Board of Directors of the
Company.
	 
	 	9.	 	INDEMNIFICATION.

	 	(a)	 	Indemnification by the Company. The Company will
indemnify and hold harmless each Holder of Option Shares which are included in
a registration statement pursuant to the provisions of Section 5 hereof and any
underwriter (as defined in the Securities Act) for such Holder, and any person
who controls such Holder within the meaning of either Section 15 of the
Securities Act or Section 20 of the Exchange Act or such underwriter within the
meaning of the Securities Act, and any officer, director, investment adviser,
employee, agent, partner, member or affiliate of such Holder (each, a “Holder
Indemnified Party”), from and against, and will reimburse each such Holder
Indemnified Party with respect to, any and all claims, actions, demands,
losses, damages, liabilities, costs and reasonably incurred expenses to which
such Holder or any such Holder Indemnified Party may become subject under the
Securities Act or otherwise, insofar as such claims, actions, demands, losses,
damages, liabilities, costs or reasonably incurred expenses arise out of or are
based

 - 9 - 

 

	 	 	 	upon (i) any untrue statement or alleged untrue statement of any material
fact contained in such registration statement, any prospectus contained
therein or any amendment or supplement thereto, or arise out of or are based
upon the omission or alleged omission to state therein a material fact
required to be stated therein or necessary to make the statements therein
not misleading, or (ii) any materially inaccurate representation or breach
of any material warranty, agreement or covenant of the Company contained
herein; provided, however, that the Company will not be liable in
any such case to the extent that any such claim, action, demand, loss,
damage, liability, cost or expense is caused by an untrue statement or
alleged untrue statement or omission or alleged omission (1) made in
conformity with information furnished by such Holder in writing specifically
for use in the preparation thereof, or (2) which was cured in an amendment
or supplement to the prospectus (or any amendment or supplement thereto)
delivered to the Holder on a timely basis to permit proper delivery thereof
prior to the date on which any Option Shares were transferred or sold.
	 
	 	(b)	 	Indemnification by the Holder. Each Holder of Option
Shares which are included in a registration statement pursuant to the
provisions of Section 5 hereof will indemnify and hold harmless the Company,
and any Person who controls the Company within the meaning of either Section 15
of the Securities Act or Section 20 of the Exchange Act, and any officer,
director, employee, agent, partner, member or affiliate of the Company (each,
an “Company Indemnified Party”) from and against, and will reimburse the
Company Indemnified Parties with respect to, any and all losses, damages,
liabilities, costs or reasonably incurred expenses to which such Company
Indemnified Parties may become subject under the Securities Act or otherwise,
insofar as such losses, damages, liabilities, costs or reasonably incurred
expenses are caused by any untrue or alleged untrue statement of any material
fact contained in such registration statement, any prospectus contained therein
or any amendment or supplement thereto, or are caused by the omission or the
alleged omission to state therein a material fact required to be stated therein
or necessary to make the statements therein, in light of the circumstances in
which they were made, not misleading, in each case to the extent, but only to
the extent, that such untrue statement or alleged untrue statement or omission
or alleged omission was so made solely in reliance upon and in conformity with
written information furnished by such Holder specifically for use in the
preparation thereof; provided, however, that the liability of any
Holder pursuant to this Section 9(b) shall be limited to an amount not to
exceed the net proceeds received by such Holder from the sale of Option Shares
pursuant to the registration statement which gives rise to such obligation to
indemnify.
	 
	 	(c)	 	Procedures. Promptly after receipt by a party
indemnified pursuant to the provisions of Section 9(a) or Section 9(b) of
notice of the commencement of any action involving the subject matter of the
foregoing indemnity

 - 10 - 

 

	 	 	 	provisions, such indemnified party will, if a claim thereof is to be made
against the indemnifying party pursuant to the provisions of Section 9(a) or
Section 9(b), notify the indemnifying party of the commencement thereof; but
the omission to so notify the indemnifying party will not relieve it from
any liability which it may have to an indemnified party otherwise than under
this Section 9 and shall not relieve the indemnifying party from liability
under this Section 9, except to the extent that such indemnifying party is
materially prejudiced by such omission. In case such action is brought
against any indemnified party and such indemnified party notifies the
indemnifying party of the commencement thereof, the indemnifying party shall
have the right to participate in, and, to the extent that it may wish,
jointly with any other indemnifying party similarly notified, to assume the
defense thereof, with counsel reasonably satisfactory to such indemnified
party, and after notice from the indemnifying party to such indemnified
party of its election to assume the defense thereof, the indemnifying party
will not be liable to such indemnified party pursuant to the provisions of
Section 9(a) or Section 9(b) for any legal or other expense subsequently
incurred by such indemnified party in connection with the defense thereof.
No indemnifying party shall be liable to an indemnified party for any
settlement of any action or claim without the consent of the indemnifying
party. No indemnifying party will consent to entry of any judgment or enter
into any settlement which does not include as an unconditional term thereof
the giving by the claimant or plaintiff to such indemnified party of a
release from all liability in respect to such claim or litigation.

	 	10.	 	SURVIVAL. The obligations of the Holder as set forth in Section 4
hereof shall survive the exercise of the Option in full and the termination of this
Option Agreement.
	 
	 	11.	 	NOTICES. Any notice required or permitted to be given hereunder shall
be in writing, and shall be either (i) personally delivered, (ii) sent by U.S.
certified or registered mail, return receipt requested, postage prepaid, or (iii) sent
by Federal Express or other reputable common carrier guaranteeing next business day
delivery, to the respective addresses of the parties set forth below, or to such other
place as any party hereto may by notice given as provided herein designate for receipt
of notices hereunder. Any such notice shall be deemed given and effective upon receipt
or refusal of receipt thereof by the primary party to whom it is to be sent.
	 
	 	 	 	To the Holder, at the address provided in the Subscription
Agreement.

 - 11 - 

 

	 	 	 	 	 
	 

	 	To the Company:
	 	ReGen Biologics, Inc.
	 

	 	 	 	509 Commerce Street
	 

	 	 	 	Franklin Lakes, NJ 07417
	 

	 	 	 	Attention: Brion D. Umidi
	 

	 	 	 	Telecopy: 201.651.5141
	 
	 	 	 	 
	 

	 	with a copy to:
	 	 
	 

	 	 	 	Pillsbury Winthrop Shaw Pittman LLP
	 

	 	 	 	1650 Tysons Boulevard
	 

	 	 	 	McLean, VA 22102
	 

	 	 	 	Attention: David C. Main, Esq.
	 

	 	 	 	Telecopy: 703.770.7901

	 	12.	 	GOVERNING LAW. This Option Agreement shall be governed by the laws of
the State of New York without reference to its principles of conflicts of laws.
	 
	 	13.	 	LITIGATION. It is the intent of the parties upon execution hereof that
this Option Agreement be deemed to have been prepared by all of the parties to the end
that no party shall be entitled to the benefit of any favorable interpretation or
construction of any term or provision hereof under any rule or law.
	 
	 	14.	 	ENTIRE AGREEMENT. This Option Agreement, together with the
Subscription Agreement and the Certificate of Designations, Preferences and Rights
relating to the Preferred Stock, contains the entire understanding between the parties
concerning the subject matter of this Option Agreement. There are no representations,
agreements, arrangements or undertakings, oral or written, between the parties relating
to the subject matter of this Option Agreement which are not fully expressed herein, in
the Subscription Agreement or in the Certificate of Designations, Preferences and
Rights relating to the Preferred Stock, and all prior agreements, to the extent they
pertain to the subject matter herein, are canceled and of no further force or effect.
This Option Agreement may not be amended or modified except in a writing signed by the
parties hereto.
	 
	 	15.	 	BINDING EFFECT. This Option Agreement shall be binding upon and inure
to the benefit of the Company and the Holder. Nothing in this Option Agreement is
intended or shall be construed to confer upon any other person any right, remedy or
claim, in equity or at law, or to impose upon any other person any duty, liability or
obligation.

 - 12 - 

 

     IN WITNESS WHEREOF, the parties have caused this Option Agreement to be duly executed as of
the date first above written.

	 	 	 	 	 	 	 
	 	 	REGEN BIOLOGICS, INC.	 	 
	 
	 	 	 	 	 	 
	 	 	 	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 

	 	 	 	 

	 	 
	 

	 	Its:	 	 	 	 
	 

	 	 	 	 

	 	 
	 
	 	 	 	 	 	 
	 	 	NAME OF HOLDER:	 	 
	 
	 	 	 	 	 	 
	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	SIGNATURE:	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 

	 	 	 	 

	 	 
	 

	 	Its:	 	 	 	 
	 

	 	 	 	 

	 	 

 - 13 - 

 

EXHIBIT A

OPTION EXERCISE FORM

                                        , 200                    

ReGen Biologics, Inc.

509 Commerce Street

Franklin Lakes, NJ 07417

Attention: Brion D. Umidi

Telecopy: 201.651.5141

     The undersigned hereby irrevocably elects to exercise its rights under the Option Agreement
dated March                     , 2007 made by and between ReGen Biologics, Inc. and the undersigned, by purchasing
the number of Option Shares listed below and hereby makes payment of the Exercise Amount listed
below.

Number of Option Shares Purchased                                               

	 	 	 
	Exercise Price Per Share:

	 	$                                        
	 
	 	 
	Exercise Amount:

	 	$                                        

     The undersigned hereby represents and warrants to the Company that all of the representations
and warranties made by the Holder in Section 7(b) of the Option Agreement are true and correct as
of the date set forth above.

     Please register and deliver the Option Shares in the name and to the address set forth below.

	 	 	 	 	 	 	 
	 

	 	Name:	 	 	 	 
	 

	 	 	 	 

	 	 
	 	 	     (Please typewrite or print in block letters)	 	 
	 
	 	 	 	 	 	 
	 	 	Address:	 	 
	 

	 	 	 	 

	 	 
	 
	 	 	 	 	 	 
	 

	 	 	 	 

	 	 
	 
	 	 	 	 	 	 
	 	 	NAME OF HOLDER:	 	 
	 
	 	 	 	 	 	 
	 	 	 	 	 

	 	 	 	 	 	 	 	 	 
	 	 	SIGNATURE OF HOLDER:	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	By:	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 

	 	 	 	Name:	 	 	 	 
	 

	 	 	 	 	 	 

	 	 
	 

	 	 	 	Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00118-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00118-of-00352.parquet"}]]